ABT-418

Из Википедије, слободне енциклопедије
ABT-418
ABT-418.png
IUPAC ime
3-metil-5-[(2S)-1-metilpirolidin-2-il]-1,2-oksazol
Identifikatori
CAS broj 147402-53-7 ДаY
ATC kod None
PubChem CID 119380
ChemSpider 106627 ДаY
ChEMBL CHEMBL274525 ДаY
Hemijski podaci
Formula C9H14N2O
Molarna masa 166.22
  (verify)

ABT-418 je lek koji je razvilo preduzeće Abbott. On deluje kao agonist na neuronskim nikotinskim acetilholinskim receptorima. Ovaj ligand se vezuje sa visokim afinitetom za α4β2, α2β2 i α7 receptore, a ne vezuje se za α3β4 receptor.[1][2] On ispoljava nootropne, neuroprotektivne i anksiolitičke efekte,[3][4][5][6] i ispitivan je za moguću primenu u lečenju Alchajmerove bolesti[7] i ADHD.[8][9][10]

Reference[уреди]

  1. Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A (1997). „Activation and inhibition of rat neuronal nicotinic receptors by ABT-418”. Br. J. Pharmacol. 120 (3): 429—438. doi:10.1038/sj.bjp.0700930. PMC 1564486. PMID 9031746. 
  2. Briggs CA, McKenna DG, Piattoni-Kaplan M (1995). „Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands”. Neuropharmacology 34 (6): 583—590. doi:10.1016/0028-3908(95)00028-5. PMID 7566493. 
  3. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS' (1994). „(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization”. J. Pharmacol. Exp. Ther. 270 (1): 310—8. PMID 7518514. 
  4. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT (1994). „(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization”. J. Pharmacol. Exp. Ther. 270 (1): 319—28. PMID 7913497. 
  5. Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (1994). „Anxiolytic-like effects of the novel cholinergic channel activator ABT-418”. J. Pharmacol. Exp. Ther. 271 (1): 353—61. PMID 7965735. 
  6. Prendergast MA; Terry AV; Jackson WJ; et al. (1997). „Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418”. Psychopharmacology (Berl.) 130 (3): 276—284. doi:10.1007/s002130050240. PMID 9151363. 
  7. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (1999). „Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease”. Psychopharmacology (Berl.) 142 (4): 334—342. doi:10.1007/s002130050897. PMID 10229057. 
  8. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999). „A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder”. Am J Psychiatry 156 (12): 1931—7. PMID 10588407. 
  9. Horrigan JP (2001). „Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder”. Expert Opin Pharmacother 2 (4): 573—586. doi:10.1517/14656566.2.4.573. PMID 11336608. 
  10. Spencer T, Biederman J (2002). „Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder”. J Atten Disord. 6 Suppl 1: S109—19. PMID 12685525.